ADJUTEC PHARMA AS

Operating

Forskning, utvikling, markedsføring og salg av nye hjelpestoffer (adjuvanter) som motvirker antibiotikaresistens, slik at kjente antibiotika virker bedre.

Forskning, innovasjon, utvikling markedsføring og salg av nye teknologier som motvirker antibiotikaresistens. Spesielt skal selskapet drive denne typen virksomhet på hjelpestoffer (adjuvanter) som motvirker antibiotikaresistens, slik at kjente antibiotika virker bedre.

Organization

CEO: JL
Jethro Lee Holter1972
Chairman of the board: ØK
Øyvind Kongstun Arnesen1957
Years since formation: 7 years; since Nov 21, 2019
Type: Limited company
VAT registered: Yes
Number of employees: 0

Ownership

Number of shares and share classes: 49,088; 1 share class
Total number of shareholders: 28; 25 companies, 3 persons

Financials

Annual total result 2025: -1,122,056; NOK
Total equity 2025: 47,221,405; NOK

Last update: Jul 15, 2026

Management

Management / administration

Name	Role	Shares
JL Jethro Lee Holter 1972	Managing Director/CEO	-

Board

Name	Role	Shares
ØK Øyvind Kongstun Arnesen 1957	Chairman	-
KE Kjell Erik Nordby 1957	Board Member	-
PR Pål Rongved 1953	Board Member	46.27 % indirectly
NR Nicolaj Refshall Weiergang 1974	Board Member	6.32 % indirectly
AF Antonius Franciscus Berkien 1968	Board Member	-
EF Espen Franzon Amundsen 1996 Resigned	Board Member	-

Others

Name	Role	Shares
R REVICOM AS	Auditor	-
S SPAREBANK 1 FORRETNINGSPARTNER ØSTLANDET AS	Accountant	-

Top 10 individual shareholders

Name	Role	Shares
PR Pål Rongved 1953	Board Member	46.27 % indirectly
CS Christen Sveaas 1956	-	9.41 % indirectly
NR Nicolaj Refshall Weiergang 1974	Board Member	6.32 % indirectly
EH Else Helene Sundt 1979	-	5.6 % indirectly
BK Bjørn Klem 1959	-	3.41 % indirectly
CN Christian Norman Weiergang 1970	-	3.24 % indirectly
CG Christian Gruner Sundt 1977	-	3.14 % indirectly
MT Magnar Tveiten 1954	-	2.09 % indirectly
KM Kjetil Myrlid Aasen 1975	-	2.03 % indirectly
TA Tom Arne Thorsen 1967	-	1.03 % indirectly

Last update: Jun 23, 2026

Ownership

Company shareholders

Name	Share class	Total number of shares	Share
P PATIAS INNOVATION AS	Ordinary shares	22,715	46.27 %
K KISTEFOS AS	Ordinary shares	4,620	9.41 %
I INVEN2 AS	Ordinary shares	2,648	5.39 %
H HELENE SUNDT AS	Ordinary shares	2,386	4.86 %
T TRYLLEBO AS	Ordinary shares	2,080	4.24 %
L LEMUREN AS	Ordinary shares	1,675	3.41 %
W WEIERGANGART AS	Ordinary shares	1,588	3.24 %
H HØSE AS	Ordinary shares	1,511	3.08 %
C CGS HOLDING AS	Ordinary shares	1,176	2.4 %
W WEIER AS	Ordinary shares	1,020	2.08 %
K KEN HOLDING AS	Ordinary shares	883	1.8 %
R RADFORSK INVESTERINGSSTIFTELSE	Ordinary shares	837	1.71 %
S SUNDT AS	Ordinary shares	726	1.48 %
F FARVATN VENTURE AS	Ordinary shares	718	1.46 %
A ADJUTEC PHARMA AS	Ordinary shares	706	1.44 %
M MYRLID AS	Ordinary shares	664	1.35 %
J JANDERSEN KAPITAL AS	Ordinary shares	664	1.35 %
W WIBO CONSULTING AS	Ordinary shares	546	1.11 %
A ALGOT INVEST AS Closed	Ordinary shares	506	1.03 %
O OSLO CANCER CLUSTER INCUBATOR AS	Ordinary shares	353	0.72 %
S STEINERT AS	Ordinary shares	300	0.61 %
S SPÅLEN GENERASJON AS	Ordinary shares	215	0.44 %
IJ Iqbal Jacob	Ordinary shares	152	0.31 %
B BASEN KAPITAL AS	Ordinary shares	136	0.28 %
SA Solveig Aars Wilhelmsen 1960	Ordinary shares	124	0.25 %
1 1540 HERITAGE CAPITAL AS	Ordinary shares	90	0.18 %
B BB-BAETIS AS	Ordinary shares	39	0.08 %
RR Rebekka Rolfsnes Hovd 1992	Ordinary shares	10	0.02 %

Shares owned by the ADJUTEC PHARMA AS

Name	Share class	Total number of shares	Share
A ADJUTEC PHARMA AS	Ordinary shares	706	1.44 %

Last update: Jun 2, 2025

Financials

in NOK

Summary

Year	2025	2024	2023	2022	2021
Total operating income	0	0	7,333,247	7,841,775	6,277,612
Annual Total Result	-1,122,056	-1,455,022	-9,533,948	-17,150,598	-3,515,968
Total assets	66,373,991	43,418,401	18,091,362	33,992,317	32,986,867
Total liabilities	19,152,586	10,073,886	23,877	6,390,884	226,916
Total equity	47,221,405	33,344,515	18,067,485	27,601,433	32,759,951

P&L

Year	2025	2024	2023	2022	2021
Total operating income	0	0	7,333,247	7,841,775	6,277,612
Total operating costs	1,531,592	2,100,420	20,379,920	31,237,050	11,493,174
Operating result	-1,531,592	-2,100,420	-13,046,673	-23,395,275	-5,215,562
Financial income/costs	78,322	219,576	-168,529	172,799	-182,943
Profit before tax	-1,453,269	-1,880,844	-13,215,202	-23,222,476	-5,398,505
Total tax & extraordinary income/cost	-331,213	-425,822	-3,681,254	-6,071,878	-1,882,537
Annual Total Result	-1,122,056	-1,455,022	-9,533,948	-17,150,598	-3,515,968

Balance overview

Year	2025	2024	2023	2022	2021
Total fixed assets	49,578,596	34,962,927	11,635,669	8,029,415	1,882,537
Total current assets	16,795,395	8,455,474	6,455,693	25,962,902	31,104,330
Total assets	66,373,991	43,418,401	18,091,362	33,992,317	32,986,867
Short term debt	1,406,316	-966,408	23,877	6,390,884	226,916
Long term debt	17,746,270	11,040,294	0	0	0
Total liabilities	19,152,586	10,073,886	23,877	6,390,884	226,916
Contributed capital	80,746,259	65,747,313	49,015,260	49,015,260	37,023,180
Retained earnings	-33,524,854	-32,402,798	-30,947,775	-21,413,827	-4,263,229
Total equity	47,221,405	33,344,515	18,067,485	27,601,433	32,759,951
Total equity and liabilities	66,373,991	43,418,401	18,091,362	33,992,317	32,986,867

Classification

21st company classification

BETA

Small company

Type of organization

Limited company

Classification of institutional sector

INNL

Domestic sectors

A_IKKE-FIN

Non-financial corporations

2100

Private non-financial incorporated enterprises

ADJUTEC PHARMA AS923 831 762